A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Burden of hospitalizations and outpatient visits associated with moderate and severe acute graft-versus-host disease in Finland and Sweden: a real-world data study




TekijätSabatelli Lorenzo, Keränen Mikko, Viayna Elisabet, Roset Montserrat, Lara Nuria, Thunström Daniel, Pfeiffer Minja, Nicklasson Malin, Itälä-Remes Maija

KustantajaSPRINGER

Julkaisuvuosi2022

JournalSupportive Care in Cancer

Tietokannassa oleva lehden nimiSUPPORTIVE CARE IN CANCER

Lehden akronyymiSUPPORT CARE CANCER

Vuosikerta30

Numero6

Aloitussivu5125

Lopetussivu5135

Sivujen määrä11

ISSN0941-4355

eISSN1433-7339

DOIhttps://doi.org/10.1007/s00520-022-06915-9

Verkko-osoitehttps://link.springer.com/article/10.1007/s00520-022-06915-9

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/174921249


Tiivistelmä

Purpose

The aim of this study was to describe patient characteristics and quantify hospital stays and outpatient visits (H&OV) following diagnosis with moderate-to-severe acute graft-versus-host disease (aGVHD) in Finland and Sweden.

Methods

A retrospective chart audit collected data from patient medical records of 3 specialized centers performing allogeneic hematopoietic stem cell transplantation (HSCT; Finland, n = 2; Sweden, n = 1). Eligible patients received allogeneic HSCT (January 1, 2016-June 30, 2017) from any donor source, were diagnosed with grade II-IV aGVHD (MAGIC or modified Glucksberg criteria) at any time from transplantation to 12 months before data collection, and were >= 18 years old at diagnosis. Criteria for comparing patients graded with modified Glucksberg and MAGIC severity scales were defined.

Results

Fifty-five patients (Finland, n = 45; Sweden, n = 10) were included. Myeloablative conditioning was the most common conditioning regimen (81.8%); immunosuppression regimens were based on combinations of methotrexate (96.4%), in vivo T-cell depletion (80.0%), cyclosporine (63.6%), mycophenolate (40.0%), and tacrolimus (34.5%). Sixteen patients (29.1%) developed grade III/IV aGVHD; skin was the most common organ involved (80.0%). Most patients required >= 1 hospital stay (89.1%; median of 2 hospitalizations per patient); 7 patients (14.3%) required admission to an intensive care unit. Median hospitalization duration from HSCT to discharge was 26 days. Most patients also required outpatient or emergency department visits (90.9%). Subgroup analyses showed longer hospital stays for patients receiving multiple treatment lines; no clear differences in H&OV were observed between prophylactic regimens.

Conclusion

Based on this retrospective study, moderate-to-severe aGVHD is associated with considerable healthcare resource utilization in Finland and Sweden, particularly in patients who received multiple lines of therapy.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 20:21